Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 9/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | RARA | P10276 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.55 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.54 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.54 |
| ▸ | PPARA | Q07869 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17060014 | 1.00 | RARB (0.62) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL28032028 | 1.00 | RARB (0.62) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL8413501 | 0.98 | RARB (0.61) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL27760653 | 0.96 | RARB (0.62) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL14118049 | 0.96 | RARB (0.62) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL27782228 | 0.94 | GPR84 (0.61) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL914005 | 0.92 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| SCHEMBL9701286 | 0.88 | RARB (0.59) | RARBMEN1ALDH1A1RARAMAPT | |
| Heptane SCHEMBL29220036 | 0.86 | PLA2G2A (0.63) | RARBMEN1ALDH1A1RARAMAPT | |
| Hexane SCHEMBL29263834 | 0.85 | PLA2G2A (0.62) | RARBMEN1ALDH1A1RARAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| EP-1956054-B1 | Phase change ink | XEROX CORP (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1958993-A1 | Phase change inks containing colorant compounds | Xerox Corporation (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1956054-A2 | Colorant compounds | Xerox Corporation (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080187664-A1 | Phase change inks containing colorant compounds | XEROX CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-20080184910-A1 | Mixture of basic dye and wax | XEROX CORPORATION | 2008-08-07 | — | — | US | disclosed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | disclosed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | disclosed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | disclosed |
| US-6706823-B2 | A CROSSLINKED COPOLYMER HAVING ALKENYL MONOMER UNITS AND MALEIMIDE MONOMER UNITS, IN A ELECTROLYTE SOLUTION; USED TO ELECTROLYTE CELLS | BRIDGESTONE CORPORATION (JP) | 2004-03-16 | — | — | US | disclosed |
| US-20030130397-A1 | A crosslinked copolymer having alkenyl monomer units and maleimide monomer units, in a electrolyte solution; used to electrolyte cells | BRIDGESTONE CORP. | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | RARB 316/4885MEN1 685/4885ALDH1A1 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.